

BIBLIOGRAPHY FOR DEPRESSION ARTICLE
www.NeuroAssist.com

REFERENCES

1. History and evolution of the monoamine hypothesis of depression. Hirschfeld RM
J Clin Psychiatry. 2000;61 Suppl 6:4-6
2. The role of serotonin in panic: evidence from tryptophan depletion studies A. C.
Pyle, S. V. Argyropoulos, D. J. Nutt Acta Neuropsychiatrica 2004; 16:79–84
3. Effect of dopamine infusion on plasma levels of growth hormone in normal
subjects and in agromegalic patients. Clin Endocrinol (Oxf). 1976 Jul;5(4):419-23
Verde G, Oppizzi G, Colussi G, Cremascoli G, Botalla L, Muller EE, Silvestrini
F, Chiodini PG, Liuzzi A
4. A multimodality investigation of cerebral hemodynamics and autoregulation in
pharmacological MRI. Magn Reson Imaging. 2007 Apr 21 Gozzi A, Ceolin L,
Schwarz A, Reese T, Bertani S, Crestan V, Bifone A.
5. Sources of human urinary epinephrine Kidney International, Vol. 51(1997), pp.
324—327 Ziegler MG, Aung M, and Kennedy B
6. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev.
1998 Aug;3(4):271-80 Birdsall TC
7. Adrenal grafting for Parkinson's disease: a role for substance P. Int J Neurosci.
1989 May;46(1-2):47-51 Barker R
8. N-methylation underlying Parkinson's disease Neurotoxicol Teratol 2002 Sep-
Oct;24(5):593 Matsubara K, Aoyama K, Suno M, Awaya T.
9. Apoptotic molecules and MPTP-induced cell death. Neurotoxicol Teratol 2002
Sep-Oct;24(5):599 Nicotra A, Parvez S.
10. Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and
heterozygotes. Mol Genet Metab. 2007 Apr;90(4):363-9. Epub 2007 Jan 19.
Verbeek MM, Geurtz PB, Willemsen MA, Wevers RA.
11. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety,
disability, and cognition J Neuropsychiatry Clin Neurosci. 2004
Summer;16(3):315-9 Menza M, Marin H, Kaufman K, Mark M, Lauritano M
12. Effect of inhibition of MAO and COMT on intrarenal dopamine and serotonin
and on renal function. Am J Physiol Regul Integr Comp Physiol. 2001
Jan;280(1):R248-54 Wang Y, Berndt TJ, Gross JM, Peterson MA, So MJ, Knox
FG
13. Acute effects of pulsatile levodopa administration on central dopamine
pharmacodynamics. Neurology. 1991 May;41(5):630-3 Davis TL, Brughitta G,
Baronti F, Mouradian MM
14. 5-HT immunoreactive hypothalamic neurons in rat and cat after 5-HTP
administration. Brain Res Bull. 1984 Jun;12(6):721-33. Sakumoto T, Sakai K,
Jouvet M, Kimura H, Maeda T
15. Transport of Monoamine Transmitters by the Organic Cation Transporter Type
2, OCT2 J Biol Chem, Vol. 273, Issue 47, 30915-30920, November 20, 1998 Dirk

- Gründemann, Sandra Köster, Nicholas Kiefer, Tilo Breidert, Martin Engelhardt, Folker Spitzenberger, Nicholas Obermüller, and Edgar Schömig
16. Blood and urine 5-hydroxytryptophan and 5-hydroxytryptamine levels after administration of two 5-hydroxytryptamine precursors in normal man. *Br J Clin Pharmacol.* 1995 Mar;39(3):327-9 Wa TC, Burns NJ, Williams BC, Freestone S, Lee MR
 17. Derivation of urinary dopamine from plasma dopa. *Clin Sci (Lond).* 1988 Nov;75(5):515-20 Zimlichman R, Levinson PD, Kelly G, Stull R, Keiser HR, Goldstein DS
 18. Handling of dopamine and dopamine sulfate by isolated perfused rat kidney. *Am J Physiol.* 1986 Jun;250(6 Pt 2):F975-9 Buu NT, Duhaime J, Kuchel O
 19. Sources of human urinary epinephrine. *Kidney Int.* 1997 Jan;51(1):324-7 Ziegler MG, Aung M, Kennedy B.
 20. Renal handling of dopa, dopamine, norepinephrine, and epinephrine in the dog. *Am J Physiol.* 1982 Jan;242(1):F56-62 Ball SG, Gunn IG, Douglas IH
 21. Utilization of tyrosine-containing dipeptides and N-acetyl-tyrosine in hepatic failure. *Hepatology.* 1995 Apr;21(4):923-8 Druml W, Hübl W, Roth E, Lochs H.
 22. The Neurobiology of Ecstasy (MDMA) National Institute of Drug Abuse (NIDA), slides 9 through 11.
<http://www.nida.nih.gov/pubs/teaching/Teaching4/Teaching.html>
 23. Platelet MAO-B Activity and Serotonin Content in Patients with Dementia: Effect of Age, Medication, and Disease *Neurochemical Research* June, 1998: 863-868 Zsuzsa Meszaros, Dora Borcsiczky, Monika Mate, Jozsef Tarcali, Tamas Szombathy, Kornelia Tekes and Kalman Magyar
 24. Effect of L-dopa administration on islet monoamine oxidase activity and glucose-induced insulin release in the mouse. *Pancreas.* 1991 Sep; 6(5): 522-7 Lundquist, I : Panagiotidis, G : Stenstrom, A
 25. Monoamine metabolism in human brain. *Arch Gen Psychiatry.* 1977 Jan;34(1):89-92. Robinson DS, Sourkes TL, Nies A, Harris LS, Spector S, Bartlett DL, Kaye IS.
 26. Catechol-O-Methyltransferase Inhibition Improves Set-Shifting Performance and Elevates Stimulated Dopamine Release in the Rat Prefrontal Cortex *Journal of Neuroscience*, June 9, 2004, 24(23):5331-5335 E. M. Tunbridge, D. M. Bannerman, T. Sharp, and P. J. Harrison
 27. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. *Am J Psychiatry.* 2004 Nov;161(11):2050-9 Roose SP, Sackeim HA, Krishnan KR, Pollock BG, Alexopoulos G, Lavretsky H, Katz IR, Hakkarainen H; Old-Old Depression Study Group.
 28. A Randomized, Placebo-Controlled Trial of Citalopram for the Treatment of Major Depression in Children and Adolescents *Am J Psychiatry* 161:1079-1083, June 2004 Karen Dineen Wagner, M.D., Ph.D., Adelaide S. Robb, M.D., Robert L. Findling, M.D., Jianqing Jin, Ph.D., Marcelo M. Gutierrez, Ph.D., and William E. Heydorn, Ph.D.
 29. Escitalopram in the Acute Treatment of Depressed Patients Aged 60 Years or Older *Am J Geriatr Psychiatry* 16:14-20, January 2008 Anjana Bose, Ph.D., Dayong Li, Ph.D., and Chetan Gandhi, Ph.D.

30. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. *Am J Psychiatry*. 2003 Jul;160(7):1277-85 Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K; Sertraline Elderly Depression Study Group.
31. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors : A retrospective study *The Journal of clinical psychiatry (J. clin. psychiatry)* ISSN 0160-6689 2005, vol. 66, n°6, pp. 705-707 POSTERNAK Michael A. ; ZIMMERMAN Mark
32. Mental Health and Substance Abuse Facts and Figures: Conquering Depression, World Health Organization 2008
33. Global burden of depressive disorders in the year 2000. *Br J Psychiatry*. 2004 May;184:386-92 Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ.
34. Mental Health, Pan American Health Organization World Health Organization 43rd Directing Council July 20, 2001
35. Evidence based review of escitalopram in treating major depressive disorder in primary care. *Int Clin Psychopharmacol*. 2004 Sep;19(5):305-10 Einarson TR
36. Elevated Monoamine Oxidase A Levels in the Brain *Arch Gen Psychiatry*. 2006;63:1209-1216 Jeffrey H. Meyer, MD, PhD; Nathalie Ginovart, PhD; Anahita Boovariwala, BSc; Sandra Sagrati, BSc; Doug Hussey, BSc; Armando Garcia, BSc; Trevor Young, MD, PhD; Nicole Praschak-Rieder, MD; Alan A. Wilson, PhD; Sylvain Houle, MD, PhD
37. O-methylation and decarboxylation of alpha-methyldopa in brain and spinal cord: depletion of S-adenosylmethionine and accumulation of metabolites in catecholaminergic neurons *Neuropharmacology*. 1976 Jul;15(7):395-402 Lo CM, Kwok ML, Wurtman RJ.
38. Depression: international intervention for a global problem, *The British Journal of Psychiatry* (2004) 184: 379-380 Mike J. Crawford, MRCPsych
39. "Polluting our future: Chemical Pollution in the U.S. that Affects Child Development and Learning" in September of 2000 under the joint efforts of The National Environmental Trust, Physicians for Social Responsibility, The Learning Disabilities Association of America
40. DBS Labs neurotransmitter data base, Tom Uncini, MD hospital base dual board certified laboratory pathologist, medical director 8723 Falcon St. Duluth, MN 55808
41. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. *Exp Neurol*. 2007 Feb;203(2):512-20. Epub 2006 Oct 17. Zeevalk GD, Manzano L, Sonsalla PK, Bernard LP.
42. Chronic oral L-DOPA increases dopamine and decreases serotonin excretions. *Am J Physiol*. 1999 Nov;277(5 Pt 2):R1476-80. Garcia NH, Berndt TJ, Tyce GM, Knox FG.
43. Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats *Neuroscience Letters* 230 (1997) 13–16 Mutsumi Matsukawa, Megumu Ogawa, Kazuhiko Nakadate, Toru Maeshima, Yukio Ichitani, Nobufumi Kawai, Nobuo Okadao.

44. Antagonistic actions of renal dopamine and 5-hydroxytryptamine: effects of amine precursors on the cell inward transfer and decarboxylation. *Br J Pharmacol.* 1996 Mar;117(6):1187-92. Soares-da-Silva P, Pinto-do-O PC.
45. Role of norepinephrine in depression. Department of Psychiatry, University of Arizona, *J Clin Psychiatry* 2000;61 Suppl 1:5-12 Delgado PL; Moreno FA,
46. Brain, kidney and liver ²⁰³Hg-methyl mercury uptake in the rat: relationship to the neutral amino acid carrier. *Pharmacol Toxicol.* 1989 Jul;65(1):17-20 Aschner M.
47. Direct determination of seleno-amino acids in biological tissues by anion-exchange separation and electrochemical detection. *J Chromatogr A.* 1995 Jul 7;706(1-2):429-36. Cavalli S, Cardellicchio N.
48. Overview of Parkinson's disease. *Pharmacotherapy.* 2007 Dec;27(12 Pt 2):155S-160S Lew M.
49. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. *Can J Neurol Sci.* 1984 Feb;11(1 Suppl):160-5 Langston JW, Ballard P.
50. Escitalopram in the treatment of depressed elderly patients. *Am J Geriatr Psychiatry.* 2005 Oct;13(10):884-91 Kasper S, de Swart H, Friis Andersen H.
51. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. *Am J Psychiatry.* 2003 Jul;160(7):1277-85. Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K; Sertraline Elderly Depression Study Group.
52. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. *Am J Psychiatry.* 2004 Nov;161(11):2050-9 Roose SP, Sackeim HA, Krishnan KR, Pollock BG, Alexopoulos G, Lavretsky H, Katz IR, Hakkarainen H; Old-Old Depression Study Group.
53. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. *J Psychiatr Res.* 2007 Apr-Jun;41(3-4):351-9. Epub 2005 Sep 12 Nemeroff CB, Thase ME; EPIC 014 Study Group
54. Sertraline in children and adolescents with major depressive disorder. *J Am Acad Child Adolesc Psychiatry.* 2006 Oct;45(10):1162-70 Donnelly CL, Wagner KD, Rynn M, Ambrosini P, Landau P, Yang R, Wohlberg CJ.
55. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. *Am J Psychiatry.* 2004 May;161(5):836-42 Lépine JP, Caillard V, Bisserte JC, Troy S, Hotton JM, Boyer P
56. Viral etiology for Parkinson's disease--a possible role of influenza A virus infection. *Jpn J Infect Dis.* 1999 Jun;52(3):89-98 Takahashi M, Yamada T.
57. Long-Term L-DOPA Treatment Causes Indiscriminate Increase in Dopamine Levels at the Cost of Serotonin Synthesis in Discrete Brain Regions of Rats. *Cell Mol Neurobiol* (2007) 27:985–996 Anupom Borah Æ Kochupurackal P. Mohanakumar
58. Neuronal regeneration after stroke. *N Engl J Med.* 2003 Jun 5;348(23):2355-6 Nadareishvili Z, Hallenbeck J.